
Currently out of the existing stock ratings of Justin Walsh, 66 are a BUY (85.71%), 11 are a HOLD (14.29%).
Analyst Justin Walsh, currently employed at JONESTRADING, has had 37.91% of price targets met with an average potential upside of 74.74%, reached in 138 days on average.
Justin Walsh has documented 139 price targets and ratings displayed on 25 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.
Most recent stock forecast was given on ATAI, ATAI Life Sciences BV at 17-Jul-2026.
Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for CATX (PERSPECTIVE THERAPEUTICS) on 12/18/2023. The price target of $15 was fulfilled within 113 days with a profit of $12.41 (479.15%), with a performance score of 42.4.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 27-Sep-2024
$13
$6.72 (107.01%)
$13
4 months 26 days ago
(23-Jun-2026)
0/4 (0%)
$7.99 (159.48%)
Buy Since 14-Nov-2024
$12
$5.72 (91.08%)
$12
4 months 27 days ago
(22-Jun-2026)
0/6 (0%)
$6.9 (135.29%)
Buy Since 23-Jun-2021
$11
$11
1 years 11 months 14 days ago
(04-Dec-2024)
0/9 (0%)
$6.47 (142.83%)
Buy Since 16-Apr-2024
$20
$20
2 years 1 months 8 days ago
(10-Oct-2024)
0/3 (0%)
$15.05 (304.04%)
Buy Since 17-Sep-2020
$11
$19
2 years 8 months 13 days ago
(05-Mar-2024)
0/5 (0%)
$6.61 (150.57%)
Which stock is Justin Walsh most bullish on?
Which stock is Justin Walsh most reserved on?
What Year was the first public recommendation made by Justin Walsh?